The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM). Investigators have identified a biomarker associated with poor outcomes in multiple myeloma (MM) that ...

Phase 1b/2 dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer. This is an ...

The Clinical Implications of Basic Research series has focused on highlighting laboratory research that could lead to advances in clinical therapeutics. However, the path between the laboratory and ...

A subset of breast cancers amplifies the ERBB2 gene at chromosomal region 17q12 and overexpresses its protein product, the ERBB2 tyrosine kinase receptor (also called HER2). This alteration is ...

Higher TIL levels in ERBB2-positive breast cancer correlate with improved DDFS and OS, suggesting a prognostic role. Patients with TILs greater than or equal to 20% may safely undergo shorter ...

"This study raises important questions deserving further consideration—notably how the location of the mutation in the HER2 protein and co-occurring mutations may impact the efficacy of HER2-targeting ...

Association of the KRAS genotype and clinicopathologic findings of resected non–small cell lung cancer. Dynamic monitoring circulating tumor DNA in plasma samples by PEAC technology for patients with ...

A team of researchers at Weizmann Institute has regenerated heart cells in adult mice using a specialized protein called ERBB2. When a heart attack strikes, heart muscle cells die and scar tissue ...

Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated with improved overall survival in patients with early-stage ERBB2-positive breast cancer. Each 5% increase in TILs was ...

Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently ...

Triple-negative breast cancer (TNBC), particularly the luminal androgen receptor (LAR) subtype, presents significant challenges due to its low proliferation rate, high metastatic potential, and ...